lemborexant Dayvigo
Selected indexed studies
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. (Transl Psychiatry, 2025) [PMID:40555730]
- ** (, 2023) [PMID:37903200]
- Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. (JAMA Netw Open, 2019) [PMID:31880796]
_Worker-drafted node — pending editorial review._
Connections
lemborexant Dayvigo is a side effect of
Sources
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. (2022) pubmed
- Insomnia Management: A Review and Update. (2023) pubmed
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. (2025) pubmed
- Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. (2019) pubmed
- Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis. (2021) pubmed
- Lemborexant: First Approval. (2020) pubmed
- PMID:37903200 (2023) pubmed
- Lemborexant (Dayvigo) for insomnia. (2020) pubmed
- PMID:38498628 (2023) pubmed
- Lemborexant (Dayvigo) for the Treatment of Insomnia. (2021) pubmed